Search

everythinglearnresearchcommunity

for

Search:↓

PCOS in lean women is a serious health condition with implications beyond fertility, affecting metabolism and increasing cardiovascular disease risk.

The document concludes that various drugs can manage symptoms and metabolic issues in women with PCOS.

Androgenetic alopecia is a common hair loss condition caused by testosterone effects on hair follicles, leading to thinner, shorter, and less pigmented hair, diagnosed using scalp dermoscopy and treated with topical minoxidil, antiandrogen agents, and 5-alpha reductase inhibitors.

PCOS women have more severe metabolic issues and higher androgen levels than hyperandrogenic women without PCOS.

Nutrients like vitamins, copper, zinc, and amino acids are crucial for healthy hair and wool growth.

Oxidative stress worsens PCOS by damaging cells and disrupting metabolism, suggesting antioxidant treatments might help.

Women with both type 2 diabetes and PCOS have worse metabolic issues but milder reproductive symptoms after sleeve gastrectomy.

17α-estradiol is a safe estrogen that might protect the brain and doesn't cause feminization, needing more research for treating brain diseases.

Lipocalin-Type Prostaglandin D2 Synthase (L-PGDS) is a protein that plays many roles in the body, including sleep regulation, pain management, food intake, and protection against harmful substances. It also affects fat metabolism, glucose intolerance, cell maturation, and is involved in various diseases like diabetes, cancer, and arthritis. It can influence sex organ development and embryonic cell differentiation, and its levels can be used as a diagnostic marker for certain conditions.

The skin acts like an endocrine organ, making hormones that affect skin diseases and respond to stress.

Insulin resistance is linked to PCOS and can lead to other health issues, but treatments like metformin can help manage symptoms.

The article concludes that better understanding gene regulation related to seasonal changes can offer insights into the mechanisms of seasonal timing in mammals.

Isotretinoin and tazarotene help treat acne, while minoxidil and finasteride promote hair growth.

Blocking IL-1 could help treat some hair loss conditions; alopecia affects liver detox systems; spironolactone is better than finasteride for female hair growth; focusing on the catagen hair phase could lead to new alopecia treatments.

Inhibitors of 11β-HSD1 show potential for treating type 2 diabetes but require more testing for safety and effectiveness.

Early detection and treatment of PCOS in teenagers is important to manage symptoms and prevent severe issues.

The document concludes that more research is needed to understand excessive hair growth in women with normal hormone levels and regular ovulation.

Oxidative stress damages hair and contributes to aging, and managing it can help maintain hair health.

Prolactin may play a significant role in skin and hair health and could be a target for treating skin and hair disorders.

In STSD patients, the body compensates for low androgen levels by increasing another enzyme's activity.

Diagnosing PCOS is challenging due to its complex and varied symptoms.

Enzymes are classified into six types and are essential for many biological processes, with only a few targeted by drugs.

The method effectively measures drug impact on DHT levels in prostate treatments.

PCOS is a common disorder in women linked to infertility and heart issues, with treatment focusing on insulin management, reducing androgens, and lifestyle changes.

Evaluate and manage androgen excess in women with a systematic approach, considering both physical and psychological impacts.

Finasteride 1 mg/day reduces semen quality without affecting hormones or sexual function.

Treating non-classic congenital adrenal hyperplasia is complex because the benefits of hormone treatment must be weighed against potential health risks.

Finasteride 1 mg reduces semen quality without affecting hormones.

Weak endocrine disruptors in mixtures can have significant effects and should be considered in risk assessments.

Men on 5-alpha-reductase inhibitors might have worse COVID-19 outcomes.